Home › Neuroendocrine Carcinoma › Washington
Neuroendocrine Carcinoma clinical trials in Washington, DC
4 studies for Neuroendocrine Carcinoma are looking for participants at sites in and around Washington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
RecruitingPhase 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
RecruitingPhase 1
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
RecruitingPhase 1
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
RecruitingObservational study
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
Neuroendocrine Carcinoma trials in other cities
- Houston, TX6 studies
- New York City, NY6 studies
- Arlington, VA5 studies
- Dallas, TX4 studies
- Los Angeles, CA4 studies
- St. Louis, MO3 studies
- Columbus, OH3 studies
- Grand Rapids, MI3 studies
- Denver, CO3 studies
- Atlanta, GA3 studies
- New Haven, CT3 studies
- Nashville, TN3 studies
Other studies in Washington
- Cancer (all types)58 studies
- Non-Small Cell Lung Cancer55 studies
- Breast Cancer46 studies
- Metastatic Cancer43 studies
- Lung Cancer41 studies
- Prostate Cancer38 studies
- Obesity33 studies
- Colorectal Cancer29 studies
- Cardiovascular Disease28 studies
- Bladder Cancer26 studies
- Acute Myeloid Leukemia24 studies
- Ovarian Cancer23 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.